About 13th Biosimilars Congregation 2019

13th Biosimilars Congregation 2019 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.
• SUE NAEYAERT, Global Head Government Affairs, Policy & Pharmaceconomics, Fresenius Kabi SwissBioSim
• SHU-YI SU, Statistical Scientist, Novartis
• IAN HENSHAW, VP, Global Head of Biosimilar Business Unit, Biogen
• MAGNUS BODIN, Director, Market Access Biosimilars, Biogen
• CHRISTIAN AGBOTON, Sr Global Brand Medical Director – Global Medical Affairs, Takeda
• JOSEPH DUNFORD, European Biosimilar Franchise Manager, Accord Healthcare
• VICTOR SASTRE, Senior MSL , Amgen Biosimilars, (Board Member MSL Society Advisory)
• FREDRIK SUNDBERG, Director Strategic Customer Relations, GE Healthcare
• HANMANT BARKATE, Vice President & Head Medical Services, (India, MEA), Glenmark (India)
• JOSEPH SALAMEH, Medical Lead, Alnylam Pharmaceuticals
• STEINAR MADSEN, Medical Director, Norwegian Medicines Agency
• LOUIS BOON, CSO, Bioceros
• LENNEKE DE WINTER, USP Director, Bioceros
• CORNELIA ULM, VP Regulatory Affairs Biosimilars, Biotec Regulatory Consulting
• KARL DAVISON, Business Development Officer, NIHR Clinical Research Network
• JUSTIN STEBBING, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College Healthcare NHS Trust
• MARIE MANLEY, Partner, Head of the UK Life Sciences Practice, Sidley Austin
• JACQUELINE MULRYNE, Counsel, Arnold & Porter LLP

For More Info visit event links:

Website of 13th Biosimilars Congregation 2019